Uncategorized

STAT+: Talawar bets bispecific approach can shake up eczema market

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today: We look at the unseemly side of scrutiny of Chinese biotech, have a SPAC for a bispecific maker, and Moderna’s mRNA ambitions enter a new phase despite years of setbacks.

Plus: Clive Meanwell sees AI’s biggest opportunity in the macro processes of biotech drug design, as opposed to the bespoke making of molecules.

Continue to STAT+ to read the full story…

​Read More

Published

on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today: We look at the unseemly side of scrutiny of Chinese biotech, have a SPAC for a bispecific maker, and Moderna’s mRNA ambitions enter a new phase despite years of setbacks.

Plus: Clive Meanwell sees AI’s biggest opportunity in the macro processes of biotech drug design, as opposed to the bespoke making of molecules.

Continue to STAT+ to read the full story…

​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version